GlassScriptPhysician profile
Matthew A Mavissakalian
NPI 1790028397
$12,902.60
in general payments reported to CMS, 2019-2025
32 companies · $1,437 in 2025
The $1,437 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,285 · 2020: $942 · 2021: $1,416 · 2022: $1,344 · 2023: $2,176 · 2024: $2,302 · 2025: $1,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,827 · Education: $88.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,826.77 |
| Education | $88.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $3,434.49 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,402.80 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,362.20 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,014.94 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Csl Behring | $608.68 | 2019-2025 | Hizentra, Andembry |
| Optinose US, INC. | $494.04 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $470.42 | 2020-2025 | Glassia, Cuvitru, Takhzyro |
| Pfizer INC. | $442.72 | 2019-2025 | |
| Genentech USA, INC. | $434.08 | 2019-2025 | Xolair |
| Amgen INC. | $408.49 | 2021-2025 | Tezspire, Actimmune |
| Alk-Abello, INC | $371.00 | 2019-2023 | Ragwitek, Grastek, Odactra |
| Grifols USA, LLC | $313.31 | 2019-2024 | Xembify, Prolastin-C Liquid |
| Biocryst US Sales Co., LLC | $297.80 | 2021-2025 | Orladeyo |
| Teva Pharmaceuticals USA, INC. | $275.26 | 2019-2022 | |
| Pharming Healthcare, INC. | $268.53 | 2020-2025 | Ruconest |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $263.95 | 2019-2024 | Auvi-Q |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.70 | 2019-2023 | Spiriva Respimat |
| Ars Pharmaceuticals Operations, INC. | $184.25 | 2025 | Neffy |
| Shire North American Group INC | $135.27 | 2019 | |
| Horizon Therapeutics Plc | $95.53 | 2022 | |
| Octapharma USA, INC. | $81.25 | 2022-2025 | Cutaquig, Octagam Immune Globulin (Human) |
| Incyte Corporation | $78.65 | 2021-2023 | Opzelura |
| Sanofi-Aventis U.S. LLC | $54.95 | 2023 | |
| Hikma Pharmaceuticals USA | $32.29 | 2023 | Ryaltris |
| Covis Pharma Gmbh | $29.79 | 2021-2022 | |
| Uswm, LLC | $28.63 | 2021 | |
| Mylan Specialty L.P. | $26.67 | 2022-2024 | Yupelri |
| Blueprint Medicines Corporation | $24.97 | 2025 | Ayvakit |
| Cycle Pharmaceuticals INC | $21.29 | 2025 | Sajazir |
| Biocryst Pharmaceuticals, INC. | $17.67 | 2020 | |
| Bio Products Laboratory USA, INC. | $17.11 | 2023 | Gammaplex, Coagadex |
| Abbvie INC. | $15.87 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Mavissakalian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.